Pelthos Therapeutics (PTHS) Assets Average (2024 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Assets Average of $128.4 million for Q4 2025, up 7219.41% year-over-year from $1.8 million in Q4 2024, and up 101.82% quarter-over-quarter from $63.6 million in Q3 2025.
Pelthos Therapeutics (PTHS) Assets Average (2024 - 2026) Analysis & Trends
Pelthos Therapeutics' Assets Average history runs 2 years deep, the most recent figure standing at $128.4 million for Q4 2025.
- In Q4 2025, Assets Average rose 7219.41% year-over-year to $128.4 million; the TTM figure through Dec 2025 stood at $128.4 million (up 7219.41% YoY), while the FY2025 annual figure was $65.9 million, up 8891.87% from the prior year.
- Assets Average for Q4 2025 stood at $128.4 million, up from $63.6 million in the prior quarter.
- The five-year high for Assets Average was $128.4 million in Q4 2025, with the low at $867014.5 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.69 Bn | 130.84 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.29 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.79 Bn | 59.60 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.44 Bn | 54.31 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.92 Bn | 27.61 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.10 Bn | 9.71 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.33 Bn | 26.17 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 19.82 Bn |
| 10 | Pelthos Therapeutics | 94.86 Mn | 70.30 Mn | 21.23 Mn | 141.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.88 Mn |
| Dec 31, 2025 | 128.42 Mn |
| Sep 30, 2025 | 63.63 Mn |
| Jun 30, 2025 | 867,014.50 |
| Mar 31, 2025 | 1.14 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | 2.37 Mn |
| Jun 30, 2024 | 3.32 Mn |
| Mar 31, 2024 | 2.06 Mn |